Cell Reports (Apr 2021)

Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies

  • Charles D. Murin,
  • Pavlo Gilchuk,
  • Philipp A. Ilinykh,
  • Kai Huang,
  • Natalia Kuzmina,
  • Xiaoli Shen,
  • Jessica F. Bruhn,
  • Aubrey L. Bryan,
  • Edgar Davidson,
  • Benjamin J. Doranz,
  • Lauren E. Williamson,
  • Jeffrey Copps,
  • Tanwee Alkutkar,
  • Andrew I. Flyak,
  • Alexander Bukreyev,
  • James E. Crowe, Jr.,
  • Andrew B. Ward

Journal volume & issue
Vol. 35, no. 2
p. 108984

Abstract

Read online

Summary: Antibodies that target the glycan cap epitope on the ebolavirus glycoprotein (GP) are common in the adaptive response of survivors. A subset is known to be broadly neutralizing, but the details of their epitopes and basis for neutralization are not well understood. Here, we present cryoelectron microscopy (cryo-EM) structures of diverse glycan cap antibodies that variably synergize with GP base-binding antibodies. These structures describe a conserved site of vulnerability that anchors the mucin-like domains (MLDs) to the glycan cap, which we call the MLD anchor and cradle. Antibodies that bind to the MLD cradle share common features, including use of IGHV1-69 and IGHJ6 germline genes, which exploit hydrophobic residues and form β-hairpin structures to mimic the MLD anchor, disrupt MLD attachment, destabilize GP quaternary structure, and block cleavage events required for receptor binding. Our results provide a molecular basis for ebolavirus neutralization by broadly reactive glycan cap antibodies.

Keywords